A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 356 participants.

Also called NCT06174766

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 356 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06174766
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06174766. Randomized; double masking; primary purpose treatment. Start 2024-05-10 (actual); primary completion 2026-01-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension Patients
Condition
Hypertension
Intervention (Drug)
HGP2304-1
Intervention (Drug)
HGP2304-2
Intervention (Drug)
RLD2209-1
Intervention (Drug)
RLD2209-2
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct06174766
Content hash
72ee63760b129f234fd02430abfa64d45b7b635ff57ad53e561dbfbc9b6e4bf1